LESAKA TECHNOLOGIES INC — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that LESAKA TECHNOLOGIES INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $659.70M | Sep 29, 2025 |
| FY2025 | Jun 30, 2024 | $564.22M | Sep 29, 2025 |
| FY2025 | Jun 30, 2023 | $527.97M | Sep 29, 2025 |
| FY2024 | Jun 30, 2022 | $222.61M | Sep 11, 2024 |
| FY2023 | Jun 30, 2021 | $130.79M | Sep 12, 2023 |
| FY2021 | Sep 30, 2020 | $35.14M | Sep 13, 2021 |
| FY2022 | Jun 30, 2020 | $144.30M | Sep 9, 2022 |
| FY2019 | Jun 30, 2019 | $51.47M | Oct 25, 2019 |
| FY2019 | Mar 31, 2019 | $86.48M | Oct 25, 2019 |
| FY2019 | Dec 31, 2018 | $97.15M | Oct 25, 2019 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $659.70M | Sep 29, 2025 |
| FY2025 | Jun 30, 2024 | $564.22M | Sep 29, 2025 |
| FY2025 | Jun 30, 2023 | $527.97M | Sep 29, 2025 |
| FY2024 | Jun 30, 2022 | $222.61M | Sep 11, 2024 |
| FY2021 | Jun 30, 2021 | $34.52M | Sep 13, 2021 |
| FY2021 | Mar 31, 2021 | $28.83M | Sep 13, 2021 |
| FY2021 | Dec 31, 2020 | $32.31M | Sep 13, 2021 |
| FY2021 | Sep 30, 2020 | $35.14M | Sep 13, 2021 |
| FY2021 | Jun 30, 2020 | $24.55M | Sep 13, 2021 |
| FY2021 | Mar 31, 2020 | $34.61M | Sep 13, 2021 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | ($87.50M) | Feb 4, 2026 |
| FY2025 | Jun 30, 2024 | ($17.44M) | Feb 4, 2026 |
| FY2025 | Jun 30, 2023 | ($35.07M) | Feb 4, 2026 |
| FY2024 | Jun 30, 2022 | ($43.88M) | Sep 11, 2024 |
| FY2021 | Jun 30, 2021 | $1.64M | Sep 13, 2021 |
| FY2021 | Mar 31, 2021 | ($6.20M) | Sep 13, 2021 |
| FY2021 | Dec 31, 2020 | ($4.53M) | Sep 13, 2021 |
| FY2021 | Sep 30, 2020 | ($28.96M) | Sep 13, 2021 |
| FY2021 | Jun 30, 2020 | ($38.88M) | Sep 13, 2021 |
| FY2021 | Mar 31, 2020 | ($34.88M) | Sep 13, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | ($27.10M) | Sep 29, 2025 |
| FY2025 | Jun 30, 2024 | $3.59M | Sep 29, 2025 |
| FY2025 | Jun 30, 2023 | ($15.35M) | Sep 29, 2025 |
| FY2024 | Jun 30, 2022 | ($40.20M) | Sep 11, 2024 |
| FY2021 | Jun 30, 2021 | ($13.60M) | Sep 13, 2021 |
| FY2021 | Mar 31, 2021 | ($14.29M) | Sep 13, 2021 |
| FY2021 | Dec 31, 2020 | ($15.21M) | Sep 13, 2021 |
| FY2021 | Sep 30, 2020 | ($10.78M) | Sep 13, 2021 |
| FY2021 | Jun 30, 2020 | ($13.18M) | Sep 13, 2021 |
| FY2021 | Mar 31, 2020 | ($14.21M) | Sep 13, 2021 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $500.0K | Sep 29, 2025 |
| FY2025 | Jun 30, 2024 | $500.0K | Sep 29, 2025 |
| FY2025 | Jun 30, 2023 | $500.0K | Sep 29, 2025 |
| FY2024 | Jun 30, 2022 | $500.0K | Sep 11, 2024 |
| FY2023 | Jun 30, 2021 | $300.0K | Sep 12, 2023 |
| FY2022 | Jun 30, 2020 | $1.60M | Sep 9, 2022 |
| FY2021 | Jun 30, 2019 | $700.0K | Sep 13, 2021 |
| FY2020 | Jun 30, 2018 | $800.0K | Sep 10, 2020 |
| FY2019 | Jun 30, 2017 | $2.00M | Oct 25, 2019 |
| FY2018 | Jun 30, 2016 | $2.30M | Dec 6, 2018 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $131.51M | Sep 29, 2025 |
| FY2025 | Jun 30, 2024 | $91.97M | Sep 29, 2025 |
| FY2025 | Jun 30, 2023 | $95.05M | Sep 29, 2025 |
| FY2024 | Jun 30, 2022 | $74.99M | Sep 11, 2024 |
| FY2023 | Jun 30, 2021 | $84.06M | Sep 12, 2023 |
| FY2022 | Jun 30, 2020 | $75.26M | Sep 9, 2022 |
| FY2021 | Jun 30, 2019 | $144.92M | Sep 13, 2021 |
| FY2020 | Jun 30, 2018 | $130.82M | Sep 10, 2020 |
| FY2019 | Jun 30, 2017 | $179.26M | Oct 25, 2019 |
| FY2018 | Jun 30, 2016 | $145.89M | Dec 6, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | ($9.12M) | Sep 29, 2025 |
| FY2025 | Jun 30, 2024 | $28.79M | Sep 29, 2025 |
| FY2025 | Jun 30, 2023 | $410.0K | Sep 29, 2025 |
| FY2024 | Jun 30, 2022 | ($37.20M) | Sep 11, 2024 |
| FY2023 | Jun 30, 2021 | ($58.37M) | Sep 12, 2023 |
| FY2022 | Jun 30, 2020 | ($46.05M) | Sep 9, 2022 |
| FY2021 | Jun 30, 2019 | ($4.46M) | Sep 13, 2021 |
| FY2020 | Jun 30, 2018 | $132.31M | Sep 10, 2020 |
| FY2019 | Jun 30, 2017 | $97.16M | Oct 25, 2019 |
| FY2018 | Jun 30, 2016 | $116.55M | Dec 6, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $17.20M | Sep 29, 2025 |
| FY2025 | Jun 30, 2024 | $12.67M | Sep 29, 2025 |
| FY2025 | Jun 30, 2023 | $16.16M | Sep 29, 2025 |
| FY2024 | Jun 30, 2022 | $4.56M | Sep 11, 2024 |
| FY2023 | Jun 30, 2021 | $4.29M | Sep 12, 2023 |
| FY2022 | Jun 30, 2020 | $5.94M | Sep 9, 2022 |
| FY2021 | Jun 30, 2019 | $9.42M | Sep 13, 2021 |
| FY2020 | Jun 30, 2018 | $9.65M | Sep 10, 2020 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $653.71M | Sep 29, 2025 |
| FY2025 | Jun 30, 2024 | $558.45M | Sep 29, 2025 |
| FY2024 | Jun 30, 2023 | $542.23M | Sep 11, 2024 |
| FY2023 | Jun 30, 2022 | $656.57M | Sep 12, 2023 |
| FY2022 | Jun 30, 2021 | $428.33M | Sep 9, 2022 |
| FY2021 | Jun 30, 2020 | $453.68M | Sep 13, 2021 |
| FY2020 | Jun 30, 2019 | $670.25M | Sep 10, 2020 |
| FY2019 | Jun 30, 2018 | $1.22B | Oct 25, 2019 |
| FY2018 | Jun 30, 2017 | $1.45B | Dec 6, 2018 |
| FY2017 | Jun 30, 2016 | $1.26B | Aug 24, 2017 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $392.33M | Sep 29, 2025 |
| FY2025 | Jun 30, 2024 | $303.16M | Sep 29, 2025 |
| FY2024 | Jun 30, 2023 | $283.33M | Sep 11, 2024 |
| FY2023 | Jun 30, 2022 | $342.22M | Sep 12, 2023 |
| FY2022 | Jun 30, 2021 | $67.37M | Sep 9, 2022 |
| FY2021 | Jun 30, 2020 | $78.49M | Sep 13, 2021 |
| FY2020 | Jun 30, 2019 | $245.23M | Sep 10, 2020 |
| FY2019 | Jun 30, 2018 | $372.75M | Oct 25, 2019 |
| FY2018 | Jun 30, 2017 | $742.75M | Dec 6, 2018 |
| FY2017 | Jun 30, 2016 | $660.28M | Aug 24, 2017 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $165.59M | Sep 29, 2025 |
| FY2025 | Jun 30, 2024 | $175.86M | Sep 29, 2025 |
| FY2024 | Jun 30, 2023 | $179.48M | Sep 11, 2024 |
| FY2023 | Jun 30, 2022 | $234.92M | Sep 12, 2023 |
| FY2022 | Jun 30, 2021 | $275.98M | Sep 9, 2022 |
| FY2021 | Jun 30, 2020 | $290.21M | Sep 13, 2021 |
| FY2020 | Jun 30, 2019 | $317.34M | Sep 10, 2020 |
| FY2019 | Jun 30, 2018 | $640.99M | Oct 25, 2019 |
| FY2018 | Jun 30, 2017 | $597.57M | Dec 6, 2018 |
| FY2017 | Jun 30, 2016 | $493.05M | Aug 24, 2017 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $199.40M | Sep 29, 2025 |
| FY2025 | Jun 30, 2024 | $138.55M | Sep 29, 2025 |
| FY2025 | Jun 30, 2023 | $133.74M | Sep 29, 2025 |
| FY2025 | Jun 30, 2022 | $162.66M | Sep 29, 2025 |
| FY2024 | Jun 30, 2021 | $29.15M | Sep 11, 2024 |
| FY2023 | Jun 30, 2020 | $24.17M | Sep 12, 2023 |
| FY2022 | Jun 30, 2019 | $37.32M | Sep 9, 2022 |
| FY2021 | Jun 30, 2018 | $52.80M | Sep 13, 2021 |
| FY2020 | Jun 30, 2017 | $75.60M | Sep 10, 2020 |
| FY2019 | Jun 30, 2016 | $179.48M | Oct 25, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $222.72M | Sep 29, 2025 |
| FY2025 | Jun 30, 2024 | $310.22M | Sep 29, 2025 |
| FY2024 | Jun 30, 2023 | $327.66M | Sep 11, 2024 |
| FY2023 | Jun 30, 2022 | $362.74M | Sep 12, 2023 |
| FY2022 | Jun 30, 2021 | $406.61M | Sep 9, 2022 |
| FY2021 | Jun 30, 2020 | $444.67M | Sep 13, 2021 |
| FY2020 | Jun 30, 2019 | $523.03M | Sep 10, 2020 |
| FY2019 | Jun 30, 2018 | $836.19M | Oct 25, 2019 |
| FY2018 | Jun 30, 2017 | $773.28M | Dec 6, 2018 |
| FY2017 | Jun 30, 2016 | $700.32M | Aug 24, 2017 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $76.52M | Sep 29, 2025 |
| FY2025 | Jun 30, 2024 | $59.07M | Sep 29, 2025 |
| FY2025 | Jun 30, 2023 | $35.50M | Sep 29, 2025 |
| FY2024 | Jun 30, 2022 | $43.94M | Sep 11, 2024 |
| FY2023 | Jun 30, 2021 | $198.57M | Sep 12, 2023 |
| FY2021 | Jun 30, 2020 | $217.67M | Sep 13, 2021 |
| FY2021 | Jun 30, 2019 | $46.07M | Sep 13, 2021 |
| FY2020 | Jun 30, 2018 | $90.05M | Sep 10, 2020 |
| FY2016 | Jun 30, 2016 | $223.64M | Aug 25, 2016 |
| FY2016 | Jun 30, 2015 | $117.58M | Aug 25, 2016 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $200.77M | Sep 29, 2025 |
| FY2025 | Jun 30, 2024 | $143.19M | Sep 29, 2025 |
| FY2025 | Jun 30, 2023 | $133.12M | Sep 29, 2025 |
| FY2023 | Jun 30, 2022 | $141.65M | Sep 12, 2023 |
| FY2022 | Jun 30, 2021 | $0 | Sep 9, 2022 |
| FY2019 | Jun 30, 2018 | $50.16M | Oct 25, 2019 |
| FY2019 | Jun 30, 2017 | $16.24M | Oct 25, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | (1) | Sep 29, 2025 |
| FY2025 | Jun 30, 2024 | 0 | Sep 29, 2025 |
| FY2025 | Jun 30, 2023 | 0 | Sep 29, 2025 |
| FY2024 | Jun 30, 2022 | 0 | Sep 11, 2024 |
| FY2021 | Jun 30, 2021 | 0 | Sep 13, 2021 |
| FY2021 | Mar 31, 2021 | 0 | Sep 13, 2021 |
| FY2021 | Dec 31, 2020 | 0 | Sep 13, 2021 |
| FY2021 | Sep 30, 2020 | 0 | Sep 13, 2021 |
| FY2021 | Jun 30, 2020 | 0 | Sep 13, 2021 |
| FY2021 | Mar 31, 2020 | 0 | Sep 13, 2021 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | (1) | Sep 29, 2025 |
| FY2025 | Jun 30, 2024 | 0 | Sep 29, 2025 |
| FY2025 | Jun 30, 2023 | 0 | Sep 29, 2025 |
| FY2024 | Jun 30, 2022 | 0 | Sep 11, 2024 |
| FY2021 | Jun 30, 2021 | 0 | Sep 13, 2021 |
| FY2021 | Mar 31, 2021 | 0 | Sep 13, 2021 |
| FY2021 | Dec 31, 2020 | 0 | Sep 13, 2021 |
| FY2021 | Sep 30, 2020 | 0 | Sep 13, 2021 |
| FY2021 | Jun 30, 2020 | 0 | Sep 13, 2021 |
| FY2021 | Mar 31, 2020 | 0 | Sep 13, 2021 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | 81.25M | Sep 29, 2025 |
| FY2025 | Jun 30, 2024 | 64.27M | Sep 29, 2025 |
| FY2024 | Jun 30, 2023 | 63.64M | Sep 11, 2024 |
| FY2023 | Jun 30, 2022 | 62.32M | Sep 12, 2023 |
| FY2022 | Jun 30, 2021 | 56.72M | Sep 9, 2022 |
| FY2021 | Jun 30, 2020 | 57.12M | Sep 13, 2021 |
| FY2020 | Jun 30, 2019 | 56.57M | Sep 10, 2020 |
| FY2019 | Jun 30, 2018 | 56.69M | Oct 25, 2019 |
| FY2018 | Jun 30, 2017 | 56.37M | Dec 6, 2018 |
| FY2017 | Jun 30, 2016 | 55.27M | Aug 24, 2017 |